BFRI vs KNSA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BFRI is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BFRI and KNSA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BFRI and KNSA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Biofrontera Inc. is a US-based commercial-stage biopharmaceutical company that markets dermatology products, with its business centered on Ameluz, a topical photodynamic therapy (PDT) gel, used together with its RhodoLED family of red-light lamps. The primary approved use is treating actinic keratosis, common precancerous skin lesions caused by sun damage. The company sells to dermatology practices in the United States and reports high gross margins on the branded therapy, though it operates at a very small revenue base compared with large pharmaceutical peers.

Full BFRI guide

Kiniksa Pharmaceuticals (Nasdaq: KNSA) is a commercial-stage biopharmaceutical company focused on immune-modulating and cardiovascular therapies. Its franchise is ARCALYST (rilonacept), an IL-1 blocker approved for recurrent pericarditis (a painful inflammatory condition of the heart lining) that it commercializes in the US under a collaboration with Regeneron. ARCALYST drove roughly $677.5 million of net product revenue in 2025, up about 62% from 2024, and the company reported roughly $214.3 million in Q1 2026 (up about 56% year over year), leading management to raise full-year 2026 ARCALYST guidance to roughly $930 to $945 million.

Full KNSA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BFRI drivers: Ameluz franchise growth; Label-expansion catalysts.
• KNSA drivers: ARCALYST adoption in recurrent pericarditis; Profitable growth profile.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Biofrontera carries risks that are typical of a speculative micro-cap and then some. For KNSA, the dominant risk is single-product concentration: essentially all revenue depends on ARCALYST in one indication, so any competitive entry, reimbursement pressure, safety signal, or eventual loss of exclusivity would be material.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BFRI if you believe its drivers more; KNSA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BFRI and KNSA guides.

BFRI. These figures are approximate and qualitative, drawn from recent public reporting, and are not precise or real-time. Biofrontera is a very small, volatile company whose numbers can change quickly. Always verify current revenue, cash, share count, and regulatory status from primary sources before making any decision.

KNSA. As of July 2026, Kiniksa carried a market cap of roughly $5.2 billion against trailing revenue near $754 million and net income around $73 million, for a trailing P/E in the mid-70s. That multiple reflects both rare biotech profitability and expectations that ARCALYST keeps compounding toward the raised 2026 guidance of roughly $930 to $945 million.

Headline figures (approximate, Jul 2026): BFRI shows revenue (ttm) Small but growing; full-year 2025 was roughly $40M with reported double-digit year-over-year growth continuing into 2026. Tiny versus large pharma peers., profitability Reported gross margins are high (near 80%), but the company has historically operated near or below net profitability at the bottom line., balance sheet Micro-cap with limited scale; may require additional financing over time, which can dilute existing holders. Verify current cash position live., valuation Trades as a speculative small-cap; conventional earnings-based multiples are of limited use when profitability is inconsistent. Sentiment is catalyst-driven.; KNSA shows revenue (ttm) ~$754M, net income (ttm) ~$73M, market cap ~$5.2B, p/e (trailing) ~74x.

BFRI and KNSA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BFRI and KNSA exposure against your real portfolio. It is not an investment adviser.